Holen Sie sich die Stockscreener-App
9.45
1.51%
-0.14
Schlusskurs vom Vortag:
$9.59
Offen:
$9.62
24-Stunden-Volumen:
112.79K
Relative Volume:
0.05
Marktkapitalisierung:
$2.84B
Einnahmen:
$455.66M
Nettoeinkommen (Verlust:
$-119.54M
KGV:
-14.77
EPS:
-0.64
Netto-Cashflow:
$-48.10M
1W Leistung:
-6.39%
1M Leistung:
-21.36%
6M Leistung:
-4.69%
1J Leistung:
-12.22%
1-Tages-Spanne:
$9.39
$9.62
1-Wochen-Bereich:
$9.37
$10.13
52-Wochen-Spanne:
$9.02
$14.57
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Firmenname
Amicus Therapeutics Inc
Sektor
Branche
Telefon
(609) 662-2000
Adresse
47 HULFISH STREET, PRINCETON, NJ
Vergleichen Sie FOLD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| FOLD | 9.445 | 2.84B | 455.66M | -119.54M | -48.10M | -0.64 |
| VRTX | 447.03 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.05 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 587.61 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.22 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.84 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-06 | Eingeleitet | Jefferies | Buy |
| 2024-05-30 | Eingeleitet | Wells Fargo | Overweight |
| 2024-05-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Fortgesetzt | Goldman | Neutral |
| 2022-01-14 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-30 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-27 | Eingeleitet | Needham | Hold |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Eingeleitet | Stifel | Hold |
| 2021-02-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-02-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-06-05 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Eingeleitet | Janney | Buy |
| 2019-01-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Eingeleitet | Citigroup | Neutral |
| 2018-08-17 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
| 2017-09-13 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-08-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-01-24 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Eingeleitet | BofA/Merrill | Buy |
| 2016-04-14 | Eingeleitet | Robert W. Baird | Neutral |
| 2016-04-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2015-09-16 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Bestätigt | Chardan Capital Markets | Buy |
Alle ansehen
Amicus Therapeutics Inc Aktie (FOLD) Neueste Nachrichten
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Victory Capital Management Inc. - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap DownShould You Sell? - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Rating Increased to Buy at StockNews.com - MarketBeat
Redmile Group, LLC Increases Stake in Amicus Therapeutics Inc - GuruFocus.com
Protein Therapeutics Market Size to be Worth USD 549.4 billion by 2031, at a CAGR of 6.3% | Transparency Market Research, Inc. - GlobeNewswire Inc.
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Acquires Shares in Amic - GuruFocus.com
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated - MSN
Avoro Capital Advisors LLC Adjusts Stake in Amicus Therapeutics Inc - GuruFocus.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by GSA Capital Partners LLP - MarketBeat
A Closer Look at 8 Analyst Recommendations For Amicus Therapeutics - Benzinga
The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts - Benzinga
Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings) - Benzinga
Amicus Therapeutics (NASDAQ:FOLD) Price Target Raised to $17.00 - MarketBeat
FOLDAmicus Therapeutics, Inc Latest Stock News & Market Updates - StockTitan
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Has A Meaningful Debt Burden - Simply Wall St
Fiera Capital Corp Reduces Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Wellington Management Group LLP's Strategic Acquisition in Amicu - GuruFocus.com
Amicus Therapeutics CEO Campbell sells $98,800 in stock - Investing.com India
Amicus Therapeutics CEO Campbell sells $98,800 in stock By Investing.com - Investing.com Australia
Amicus Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Amicus Therapeutics (NASDAQ:FOLD) Downgraded by StockNews.com to Hold - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Given New $15.00 Price Target at Guggenheim - MarketBeat
Teva’s Galafold generic for Fabry disease may be available in US - Fabry Disease News
Here's Why Amicus Therapeutics (FOLD) is a Strong Momentum Stock - Yahoo Finance
Needham & Company LLC Reiterates Hold Rating for Amicus Therapeutics (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2024 Earnings Call Transcript - Insider Monkey
Peeling Back The Layers: Exploring Amicus Therapeutics Through Analyst Insights - Benzinga
Here's What Key Metrics Tell Us About Amicus Therapeutics (FOLD) Q3 Earnings - Yahoo Finance
Earnings call: Amicus Therapeutics reports robust Q3 growth, raises guidance - Investing.com India
Earnings call: Amicus Therapeutics reports robust Q3 growth, raises guidance By Investing.com - Investing.com Canada
Amicus Therapeutics Q3 2024 Earnings Preview - MSN
Old West Investment Management LLC Grows Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates - Yahoo Finance
Amicus Therapeutics Inc (FOLD) Q3 2024 Earnings: Revenue Surges - GuruFocus.com
Amicus Therapeutics: Q3 Earnings Snapshot - San Antonio Express-News
Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates - The Manila Times
Creative Planning Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Bradley L. Campbell Sells 7,500 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock - MarketBeat
Amicus Therapeutics CEO Bradley Campbell sells $85,959 in stock By Investing.com - Investing.com Canada
Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know - MSN
Allspring Global Investments Holdings LLC Has $172,000 Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $17.13 - Defense World
Blue Trust Inc. Boosts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Cradle of Cures - Site Selection Magazine
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024 - GlobeNewswire
Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $17.13 - MarketBeat
abrdn plc Boosts Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Lowered by StockNews.com - Defense World
Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Amicus Therapeutics (FOLD) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat
Finanzdaten der Amicus Therapeutics Inc-Aktie (FOLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):